Is Concerta (methylphenidate) 72 mg equivalent to Vyvanse (lisdexamfetamine) 60 mg for a patient with Attention Deficit Hyperactivity Disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Direct Dose Equivalence Between Concerta 72 mg and Vyvanse 60 mg

There is no established direct milligram-to-milligram equivalence between Concerta (methylphenidate) 72 mg and Vyvanse (lisdexamfetamine) 60 mg, as these are different stimulant classes with distinct pharmacokinetic profiles and mechanisms of action. However, based on available conversion guidance, Vyvanse 60 mg would generally require a higher dose of Concerta than 72 mg to achieve comparable clinical effect.

Practical Conversion Guidance

When switching from Vyvanse 70 mg (the closest studied dose to 60 mg) to OROS-methylphenidate (Concerta), the recommended equivalent is 54-72 mg once daily 1. This suggests that Vyvanse 60 mg would likely correspond to Concerta in the range of approximately 54-72 mg, making 72 mg Concerta potentially equivalent or slightly higher than Vyvanse 60 mg 1.

Key Pharmacological Differences

  • Duration of action differs substantially: Concerta provides 12 hours of coverage, while Vyvanse (lisdexamfetamine) provides 13-14 hours of symptom control 2, 1
  • Mechanism differences: Lisdexamfetamine is a prodrug requiring rate-limited hydrolysis by red blood cells to yield d-amphetamine, creating more sustained and larger effects on catecholaminergic neurotransmission than methylphenidate 3
  • Neurochemical profiles diverge: Lisdexamfetamine increases dopamine, noradrenaline, and serotonin in both prefrontal cortex and striatum, while methylphenidate primarily affects dopamine and noradrenaline without significant serotonergic effects 3

Clinical Response Considerations

  • Both medications have similar overall response rates of 70-80% in ADHD patients, but individual response varies significantly between stimulant classes 1, 4
  • The 72 mg Concerta dose represents the maximum approved daily dose, while Vyvanse 60 mg is below the maximum of 70 mg, suggesting the Concerta patient may be at ceiling dose while the Vyvanse patient has room for titration 5, 1
  • Regression analysis shows lisdexamfetamine produces greater increases in extracellular dopamine without locomotor activation compared to methylphenidate, indicating different therapeutic windows despite similar clinical efficacy 3

Practical Switching Algorithm

If switching between these medications:

  • From Vyvanse 60 mg to Concerta: Start at 54 mg once daily in the morning, assess after 1 week, and increase to 72 mg if response is inadequate 1
  • From Concerta 72 mg to Vyvanse: Start at 50-60 mg once daily in the morning, as the patient is already on maximum methylphenidate dose 1
  • No cross-taper is necessary—the new medication can be started the next day after discontinuing the previous stimulant 2
  • Monitor ADHD symptom control, blood pressure, heart rate, sleep quality, and appetite during the first week after any switch 1

Important Caveats

  • Individual patient response trumps theoretical equivalence—some patients respond preferentially to amphetamine-based versus methylphenidate-based stimulants regardless of dose 4, 6
  • Even with optimal dosing based on behavioral measures, subtle neurocognitive impairments may persist, so functional outcomes beyond symptom checklists should guide final dose selection 6
  • The concept of "equivalence" assumes similar clinical endpoints, but duration of coverage needs may differ—a patient requiring 13-14 hours of coverage may not achieve equivalent functional outcomes with 12-hour Concerta even at higher doses 2, 1

References

Guideline

Alternative ADHD Medications When Adderall and Vyvanse Are Unavailable

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Methylphenidate Extended-Release Formulations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Current Pharmacological Treatments for ADHD.

Current topics in behavioral neurosciences, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the differences between Jornay (methylphenidate hydrochloride) and Adderall XR (amphetamine mixed salts) for treating Attention Deficit Hyperactivity Disorder (ADHD) in adults?
What are affordable alternatives to Vyvanse (lisdexamfetamine) for a patient with Attention Deficit Hyperactivity Disorder (ADHD) who responds well to the medication but finds it unaffordable?
Can an 18-year-old patient with Attention Deficit Hyperactivity Disorder (ADHD) who has been taking 72mg of Concerta (methylphenidate) for 6 months continue their current medication regimen?
What are the treatment options for Attention Deficit Hyperactivity Disorder (ADHD) in adults?
What is the next step in optimizing medication for a patient with Attention Deficit Hyperactivity Disorder (ADHD) who has been taking 12.5mg Adzenys (amphetamine) and 10-20mg Adderall IR (dextroamphetamine and amphetamine) for approximately 2 years with inadequate control of executive function and task initiation?
What is the recommended methylcobalamin (Vitamin B12) injection regimen for patients with neurological symptoms due to Vitamin B12 deficiency?
What is the appropriate management for a 35-year-old female with eosinophilia, elevated inflammatory markers, dyslipidemia, and a positive Phadiatop result indicating an allergic condition?
What is methylcobalamin (Vitamin B12) used for?
What happens if a patient with a history of kidney or liver disease, heart conditions, or previous allergic reactions overdoses on methylcobalamin (Vitamin B12) injections?
How do you classify and manage mild, moderate, and severe hyperthyroidism in a patient with a history of cardiovascular disease?
What are the strategies to minimize the risk of postoperative cognitive dysfunction (POCD) in elderly patients with pre-existing cognitive impairment or dementia undergoing general anesthesia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.